NEWS
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, a leader in broad-spectrum antiviral nanomedicines, has developed NV-387, a first-in-class antiviral agent targeting RSV, COVID-19, Influenza, and other viruses. NV-387 employs novel host-mimetic technology to remain effective despite viral mutations. It has outperformed existing drugs such as remdesivir, Tamiflu, and TPOXX in preclinical studies. NV-387 has successfully completed Phase I human trials with no reported adverse events, demonstrating strong safety profiles. The drug is now poised for Phase II trials. NanoViricides holds exclusive perpetual licenses for several antiviral treatments and collaborates with Karveer Meditech in India.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1066Followers
68Following
7336Visitors
Follow